Amneal Pharmaceuticals, Inc. AMRX Specialty — Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — other?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — other of $905K in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — other changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — other decreased by 27.5% year-over-year, from $1.25M to $905K.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — other?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — other has grown at a 1.1% compound annual growth rate (CAGR), from $5.41M to $5.58M.
- What does specialty — other mean?
- Aggregates minor or miscellaneous operational costs that are not captured in specific functional categories within the specialty segment. It is used to track residual overhead and administrative expenses.